IRD Opus Genetics, Inc.
Healthcare$4.09-3.99%ClosedMarket Cap: $332.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-80.76
P/S
28.94
EV/EBITDA
-5.61
DCF Value
$-0.28
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
49.6%
Operating Margin
-359.1%
Net Margin
-892.4%
ROE
6068.8%
ROA
-160.1%
ROIC
-74.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.2M | 99.4% | $-14.4M | $-65.5M | $— | — |
| Q4 null | $3.9M | 100.0% | $-11.5M | $-16.5M | $— | — |
| FY null | $14.2M | 100.0% | $-38.6M | $-49.6M | $— | — |
| Q3 null | $3.1M | 100.0% | $-8.3M | $-17.5M | $— | — |
| Q2 null | $2.9M | -109.0% | $-8.9M | $-7.4M | $— | — |
| Q1 null | $4.4M | 100.0% | $-9.9M | $-8.2M | $— | — |
| Q4 null | $4.3M | -80.8% | $-38.0M | $-35.1M | $— | — |
| FY null | $11.0M | 100.0% | $-62.1M | $-57.5M | $— | — |
| Q3 null | $3.9M | 100.0% | $-8.0M | $-7.5M | $— | — |
| Q2 null | $1.1M | 100.0% | $-8.3M | $-7.8M | $— | — |
| Q1 null | $1.7M | 100.0% | $-7.7M | $-7.1M | $— | — |
| Q4 2023 | $1.7M | -177.8% | $-5.4M | $-4.8M | $-0.22 | — |